menu
    • menu
    [{"orgOrder":0,"company":"Biorasi","sponsor":"Alzamend Neuro","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"ALZN002","moa":"||Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Biorasi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biorasi \/ Biorasi","highestDevelopmentStatusID":"7","companyTruncated":"Biorasi \/ Biorasi"},{"orgOrder":0,"company":"Biorasi","sponsor":"Alzamend Neuro","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Partnership","leadProduct":"ALZN002","moa":"||Amyloid-beta-protein","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Biorasi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Biorasi \/ Biorasi","highestDevelopmentStatusID":"7","companyTruncated":"Biorasi \/ Biorasi"},{"orgOrder":0,"company":"Biorasi","sponsor":"Therapeutic Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"||Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biorasi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biorasi \/ Biorasi","highestDevelopmentStatusID":"10","companyTruncated":"Biorasi \/ Biorasi"},{"orgOrder":0,"company":"Biorasi","sponsor":"Therapeutic Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Umbilical Cord Mesenchymal Stem Cell","moa":"||Stem cell proliferation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biorasi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Biorasi \/ Biorasi","highestDevelopmentStatusID":"10","companyTruncated":"Biorasi \/ Biorasi"},{"orgOrder":0,"company":"Biorasi","sponsor":"Longeveron","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-10 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Biorasi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biorasi \/ Biorasi","highestDevelopmentStatusID":"8","companyTruncated":"Biorasi \/ Biorasi"},{"orgOrder":0,"company":"Biorasi","sponsor":"Longeveron","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Inapplicable","moa":"||IL-10 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Biorasi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biorasi \/ Biorasi","highestDevelopmentStatusID":"8","companyTruncated":"Biorasi \/ Biorasi"},{"orgOrder":0,"company":"Biorasi","sponsor":"Alfasigma","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ITALY","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Rifaximin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Dermatology","graph2":"Phase II","graph3":"Biorasi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Delayed Release","sponsorNew":"Biorasi \/ Biorasi","highestDevelopmentStatusID":"8","companyTruncated":"Biorasi \/ Biorasi"},{"orgOrder":0,"company":"Biorasi","sponsor":"Citius Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Protein Biosynthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Biorasi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Biorasi \/ Citius Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Biorasi \/ Citius Pharmaceuticals"},{"orgOrder":0,"company":"Biorasi","sponsor":"Longeveron","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Allogeneic Mesenchymal Stem Cell","moa":"||Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Biorasi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biorasi \/ Biorasi","highestDevelopmentStatusID":"8","companyTruncated":"Biorasi \/ Biorasi"},{"orgOrder":0,"company":"Biorasi","sponsor":"AOBiome Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"B244","moa":"||IL-4 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Biorasi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Biorasi \/ Biorasi","highestDevelopmentStatusID":"8","companyTruncated":"Biorasi \/ Biorasi"},{"orgOrder":0,"company":"Biorasi","sponsor":"Stemedica Cell Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Mesenchymal Bone Marrow Cell","moa":"||Progenitor cell","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Biorasi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biorasi \/ Biorasi","highestDevelopmentStatusID":"8","companyTruncated":"Biorasi \/ Biorasi"}]

    Find Clinical Drug Pipeline Developments & Deals by Biorasi

    Menu

    Biorasi

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Biorasi

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Biorasi

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALZN002,Inapplicable

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Recipient : Alzamend Neuro

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study in Subjects With Mild-to-Moderate Alzheimer's Dementia

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            April 28, 2023

                            Lead Product(s) : ALZN002,Inapplicable

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Alzamend Neuro

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Biorasi

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Biorasi

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALZN002,Inapplicable

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Recipient : Alzamend Neuro

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Alzamend Neuro Partners With Biorasi to Conduct a First-in-Human, Randomized, Double-Blind, Placebo-Controlled...

                            Details : ALZN002 is a proprietary active immunotherapy product. It consists of autologous DCs, which are activated WBCs taken from each individual patient that are then engineered outside of the body to attack Alzheimer’s-related amyloid-beta proteins.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            April 01, 2023

                            Lead Product(s) : ALZN002,Inapplicable

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Recipient : Alzamend Neuro

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Biorasi

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Biorasi

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Laromestrocel,Inapplicable

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Recipient : Longeveron

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Longeveron Announces Completion of Enrollment in Phase 2a Trial of Lomecel-B™ for the Treatment of Alzheimer...

                            Details : Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of adult donors. Longeveron is advancing Lomecel-B through clinical trials in 3 indications: Hypoplastic Left Heart Syndrome, Alzheimer’s Disease, and...

                            Product Name : Lomecel-B

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            October 11, 2022

                            Lead Product(s) : Laromestrocel,Inapplicable

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Recipient : Longeveron

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Biorasi

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Biorasi

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Minocycline Hydrochloride,Ethanol,Edetate Calcium Disodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Citius Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Citius Pharmaceuticals to Accelerate Phase 3 Mino-Lok Trial by Expanding Trial Sites Internationally

                            Details : Mino-Lok (minocycline) is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs).

                            Product Name : Mino-Lok

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 05, 2022

                            Lead Product(s) : Minocycline Hydrochloride,Ethanol,Edetate Calcium Disodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Citius Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Biorasi

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Biorasi

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Umbilical Cord Mesenchymal Stem Cell,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Therapeutic Solutions

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Therapeutic Solutions International Selects Premier Regenerative Medicine CRO Biorasi to Initiate and Run Phas...

                            Details : The unprecedented results from JadiCells allowed for 100% patient survival at one month in subjects treated who were less than 85 years old, and 91% survival in subjects of all ages, compared to 42% survival in the control group.

                            Product Name : JadiCell

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            March 28, 2022

                            Lead Product(s) : Allogeneic Umbilical Cord Mesenchymal Stem Cell,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Therapeutic Solutions

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Biorasi

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Biorasi

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Mesenchymal Stem Cell,Inapplicable

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Recipient : Longeveron

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lomecel-B Effects on Alzheimer's Disease

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 10, 2022

                            Lead Product(s) : Allogeneic Mesenchymal Stem Cell,Inapplicable

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Recipient : Longeveron

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Biorasi

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Biorasi

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Umbilical Cord Mesenchymal Stem Cell,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Recipient : Therapeutic Solutions

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Therapeutic Solutions International Announces Launching of Phase III Clinical Trial for Treating COVID-19 Lung...

                            Details : JadiCell (mesenchymal stem cells), was shown to be 100% effective in saving the lives of COVID-19 patients under age of 85 in a double-blind, randomized, placebo controlled clinical trial with patients in the ICU on a ventilator.

                            Product Name : JadiCell

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            February 05, 2022

                            Lead Product(s) : Allogeneic Umbilical Cord Mesenchymal Stem Cell,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Recipient : Therapeutic Solutions

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Biorasi

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Biorasi

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rifaximin,Inapplicable

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Recipient : Alfasigma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibiotic

                            Upfront Cash : Inapplicable

                            December 09, 2021

                            Lead Product(s) : Rifaximin,Inapplicable

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Recipient : Alfasigma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Biorasi

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Biorasi

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Laromestrocel,Inapplicable

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Recipient : Longeveron

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease Trial

                            Details : LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors.

                            Product Name : Lomecel-B

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            May 11, 2021

                            Lead Product(s) : Laromestrocel,Inapplicable

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Recipient : Longeveron

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Biorasi

                            U.S.A arrow
                            EPSC
                            Not Confirmed

                            Biorasi

                            U.S.A arrow
                            EPSC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Allogeneic Mesenchymal Bone Marrow Cell,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : Stemedica Cell Technologies

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Inapplicable

                            March 03, 2021

                            Lead Product(s) : Allogeneic Mesenchymal Bone Marrow Cell,Inapplicable

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : Stemedica Cell Technologies

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth